erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.
elizabeth loder, md, professor of neurology, harvard medical school; chief, division of headache, brigham & women's hospital.
.
.
her twins' cases were published, along with that of a third baby boy, in april in the
.